Why Sanofi Genzyme is Still Defying the Odds Five Years After Being Acquired

So often is the trend in Biotech than when a large Pharma acquires another, 2 or 3 years down the line that subsidiary tends to flop…or perhaps take a different market trajectory than planned. For example, when Merck KGaA (Germany) bought Serono in 2012, the Swiss biotech then went and fired around 10,000 people at their Geneva base…

However, Sanofi and Genzyme appear to have exceeded expectations in the Biotech world. Genzyme was acquired by Sanofi for $20Bn back in 2011, which is one of the biggest Biotech deals in history.